Loading
Latest filing published 09 Jun 2022 for Clarus Therapeutics Holdings, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Elizabeth Cermak, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Pozen Inc /NC and Clarus Therapeutics Holdings, Inc. We count 8 filings; the first trade dates from 14 March 2011 and the latest from 7 June 2022.
No open-market sale appears; the market trades are 1 purchase worth €34k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 7 share grants.
The latest filing, published on 9 June 2022, reports a share grant in Clarus Therapeutics Holdings, Inc. The most recent open-market purchase was published on 16 March 2011, 5,701 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations